Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. PhRMA CEO Steve Ubl is stepping down.
Biotech investors are grappling with pressure from AI and rising competition from Chinese labs, even though firms sit on large cash reserves. Also, the Trump administration is stepping back from the “indirect cost” fight at the NIH, and new data suggest genetics may modestly influence responses to GLP-1 drugs.
Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 09 Apr 2026.
The item focuses on STAT+: Genetics may shape GLP-1 outcomes, slightly.
Review the original article for the full source wording and details.